Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mirum Pharmaceuticals Inc.
Headquarters: Foster City, CA, United States of America
Website: http://www.mirumpharma.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Christopher Peetz, MBA
Number Of Employees: 322
Enterprise Value: $2,002,507,262
PE Ratio: -24.87
Exchange/Ticker 1: NASDAQ:MIRM
Exchange/Ticker 2: N/A
Latest Market Cap: $2,258,574,336
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Dec 4, 2024
Data Byte
Nine PDUFA dates on FDA’s December calendar
Ionis’ first wholly owned product among three rare disease therapies up for approval. BMS expecting decision on subcutaneous Opdivo
BioCentury | Aug 27, 2024
Management Tracks
Patel joins Sana as EVP, CSO
Plus: Ian Clements named CFO of Marea, new role at BII for Soni and more
BioCentury | Jun 1, 2024
Data Byte
EMA’s CHMP recommends new indications for Dupixent, Skyrizi
May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy
BioCentury | Apr 27, 2024
Data Byte
FDA label expansions: March brought full approvals of Elahere, Rybrevant
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
BioCentury | Mar 23, 2024
Management Tracks
Braunstein retiring as Idorsia CMO
Plus: Lys names Vounatsos chair and updates from Theolytics, BeiGene, Renibus and MaaT
BioCentury | Jan 18, 2024
Management Tracks
Paul stepping down as Karuna CSO
Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase
BioCentury | Dec 19, 2023
Deals
Dec. 18 Quick Takes: Illumina to divest Grail
Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint
BioCentury | Oct 21, 2023
Management Tracks
Daly to succeed McEnany as Catalyst CEO
Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
Items per page:
1 - 10 of 36